This fruit filled smash cake is the perfect celebratory desert for your little one. Parents, it's easy to make, and your toddlers will love it!
This fruit filled smash cake is the perfect celebratory desert for your little one. Parents, it's easy to make, and your toddlers will love it!
The 40-year-old TV presenter thought sweetcorn grew underground like carrots.
Revenue from RF GaN-enabled devices experienced another year of fast growth, increasing by close to 30 percent in 2020 to cross the $1 billion barrier for the first time. The Strategy Analytics Advanced Semiconductor Applications (ASA) and Advanced Defense Systems (ADS) report "RF GaN Device Market Forecast: 2020-2025" identifies base station and defense applications as the prime drivers for this RF GaN revenue growth. The report forecasts that the long-term prospects for RF GaN revenue growth look good, with 5G base station and defense applications pushing revenue to almost $2 billion in 2025.
Philip Morris International Inc. (PMI) (NYSE: PM) today published its Integrated Report, a comprehensive overview of the company’s environmental, social, and governance (ESG) performance and its progress toward its purpose of delivering a smoke-free future. This includes its 2025 ambitions to have switched more than 40 million adult smokers to its smoke-free products, with half from non-OECD countries, and for smoke-free products to account for more than 50 percent of PMI’s total net revenues. Further accelerating PMI’s transformation, this year the company introduced two new 2025 ambitions, linked to its Business Transformation Metrics: for its smoke-free products to be available in 100 markets and for at least USD 1 billion in annual net revenues to come from "beyond nicotine" products. The Integrated Report also outlines case studies of early indications of PMI’s smoke-free products’ impacts in markets where such products have a meaningful presence.
The buy now, pay later business delivers more revenue, but much greater losses in the fiscal third quarter.
A YouGov poll found one in five think they should keep their titles but stop using them.
The Clinic by Cleveland Clinic™, a transformative joint venture between Cleveland Clinic and Amwell® (NYSE: AMWL) that aligns world-class clinical expertise with the power of innovative digital health technologies, announced today that its virtual second opinion solution, available to health plans, employers and consumers, will now include multidisciplinary case analysis. The Clinic’s virtual second opinion offering provides patients, including those with complex medical conditions, the ability to obtain support from Cleveland Clinic’s world-renowned multidisciplinary panels, whose diversity of expertise ensures the most comprehensive and coordinated second opinion and treatment plan is offered.
This Morning host Holly Willoughby left co-host Philip Schofield aghast when she revealed a hilarious faux pas that she'd made while attempting to grow corn on the cob. Credit: @thismorning via Twitter
Coast Capital, which holds nearly 14% of the transport operator, late on Monday urged fellow shareholders to vote against the proposed disposal of the "crown jewel assets", unless the terms of the proposal were "rapidly and substantively improved". FirstGroup said, "The sale followed a comprehensive and competitive process in order to seek the best possible price for First Student and First Transit, which was well-publicised for more than a year." The company, in its disposal announcement last month, said it would use the sale proceeds to pay down debt, including the UK government's coronavirus aid, contribute to its UK pension schemes and return about 365 million pounds ($518.48 million) to shareholders.
The live sports streaming and soon-to-be-launched sports-betting platform said total revenue more than doubled, advertising sales tripled, subscription revenue surged 131%, and the number of subscribers exceeded 590,000, more than double the total from a year ago. Sitting at the confluence of three massive trends -- cord-cutting, advertising dollars transitioning to connected devices, and sports betting -- fuboTV is uniquely positioned to capture the growth of all three, and its earnings report indicates its journey is well underway. Rather, as fuboTV management notes in the latest shareholder letter, consumers are discovering "they can cut the cord without losing access to the sports teams, live channels, and content they love" by subscribing to fuboTV.
On May 18, 2021, mortgage refinance rates rose a bit compared with yesterday. If you own a home, refinancing your current mortgage loan could potentially save you money if you can drop your interest rate on your existing mortgage debt.
Condizioni di conservazione più flessibili per il vaccino anti-Covid Comirnaty* di BioNTech/Pfizer: una volta scongelato, potrà restare in un frigorifero normale fino a un mese, annuncia l'Agenzia europea del farmaco Ema, il cui Comitato per i medicinali per uso umano (Chmp) ha raccomandato una modifica alle condizioni di conservazione approvate per il prodotto. Una novità che faciliterà la gestione del vaccino a mRna nei centri di vaccinali di tutta l'Ue, sottolinea l'ente regolatorio. "Questa modifica - riferisce l'Ema - estende da 5 giorni a un mese (31 giorni) il periodo di conservazione della fiala scongelata e non aperta a 2-8°C, le temperature di un normale frigorifero". Gli esperti del Chmp si sono espressi dopo avere valutato "ulteriori dati di studi di stabilità presentati all'Ema dal titolare dell'autorizzazione all'immissione in commercio" Aic. Le modifiche descritte saranno incluse tra le informazioni relative a Comirnaty pubblicate sul sito web dell'Ema, e saranno inserite dal titolare dell'Aic nelle istruzioni allegate al prodotto. L'Ema prevede che "una maggiore flessibilità nella conservazione e nella manipolazione del vaccino avrà un impatto significativo sulla pianificazione e la logistica" della vaccinazione negli Stati membri dell'Ue.
For investors interested in getting started with options, the way these instruments work can seem intimidating. An option's price is made up of two components: intrinsic value and time value. In this segment from Motley Fool Live that first aired May 7, Motley Fool Canada analyst Jim Gillies and Fool.
Smart Implantable Pumps Market Research Report by Type (Micro Pumps and Perfusion Pumps), by Application (Cardiovascular and Pain & Spasticity), by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, May 18, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Smart Implantable Pumps Market Research Report by Type, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05911520/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Smart Implantable Pumps Market is expected to grow from USD 1,170.40 Million in 2020 to USD 1,899.29 Million by the end of 2025.2. The Global Smart Implantable Pumps Market is expected to grow from EUR 1,026.23 Million in 2020 to EUR 1,665.33 Million by the end of 2025.3. The Global Smart Implantable Pumps Market is expected to grow from GBP 912.32 Million in 2020 to GBP 1,480.48 Million by the end of 2025.4. The Global Smart Implantable Pumps Market is expected to grow from JPY 124,911.86 Million in 2020 to JPY 202,702.66 Million by the end of 2025.5. The Global Smart Implantable Pumps Market is expected to grow from AUD 1,699.58 Million in 2020 to AUD 2,758.02 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Smart Implantable Pumps to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Type, the Smart Implantable Pumps Market studied across Micro Pumps and Perfusion Pumps. Based on Application, the Smart Implantable Pumps Market studied across Cardiovascular and Pain & Spasticity. Based on End User, the Smart Implantable Pumps Market studied across Ambulatory Surgical Centers and Hospitals. Based on Geography, the Smart Implantable Pumps Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Smart Implantable Pumps Market including Abbott Laboratories, Absolute Medical Services, Inc, Baxter International, Becton Dickinson (BD), Berlin Heart Inc, Bioptechs, Chemyx Inc, Cognos Therapeutics, Inc., Flowonix Medical Inc, Fresenius Kabi, Intarcia Therapeutics, Inc., Ivenix, Inc., Levitronix, Medtronic, plc., Micrel Medical Devices, Q Core Medical Ltd, and Tricumed Medizintechnik GmbH. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Smart Implantable Pumps Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Smart Implantable Pumps Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Smart Implantable Pumps Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Smart Implantable Pumps Market?4. What is the competitive strategic window for opportunities in the Global Smart Implantable Pumps Market?5. What are the technology trends and regulatory frameworks in the Global Smart Implantable Pumps Market?6. What are the modes and strategic moves considered suitable for entering the Global Smart Implantable Pumps Market?Read the full report: https://www.reportlinker.com/p05911520/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
(Bloomberg) -- As the world begins to emerge from lockdown, some hedge funds are slashing technology investments that thrived in the work-from-home era.Philippe Laffont’s Coatue Management slashed many of its tech holdings that have benefited from the pandemic-induced lockdowns, including most of its stake in fitness-equipment maker Peloton Interactive Inc. The fund cut its exposure to cyber-security solutions company Crowdstrike Holdings Inc. and and Zoom Video Communications Inc. in half. Overall, its exposure to technology stocks fell by about 8%, data compiled by Bloomberg show.Alex Sacerdote’s Whale Rock Capital Management exited its investment in Zoom, and decreased stakes in Peloton and Crowdstrike. The hedge fund trimmed its overall exposure to tech stocks by about 5%, Bloomberg data show.The filings offer a glimpse into the maneuvering by major hedge fund managers and other investors during the first quarter of 2021, a tumultuous period for the industry marked by a Reddit-fueled trading frenzy and the implosion of Bill Hwang’s Archegos Capital Management. At the same time, investors are looking toward a post-Covid 19 economic recovery where the world gradually reopens and people return to work.On average, hedge funds gained 4.6% in the first three months of the year, according to data compiled by Bloomberg. That lagged behind the S&P 500 Index, which rose 6.2% on a total-return basis.Lee Ainslie’s Maverick Capital joined fellow so-called Tiger cub Coatue in trimming its overall exposure to tech stocks by almost 17%, Bloomberg data show. It ditched minor holdings in Zoom and DocuSign Inc., a popular app for signing contracts and other documents digitally.Trading in Amazon.com Inc., which had soared in the pandemic amid a boom in online shopping by customers stuck at home, was a mixed bag among the Tiger cubs. While both Maverick and Coatue added to their holdings of the behemoth retailer, Viking Global Management slightly trimmed its exposure. Shares of Amazon have climbed 5.7% since the end of the first quarter and are little changed this year.Other findings from first quarter 13F filings include:Financials were key as they broadly trailed other cyclical sectors due in part to low interest rates. Dan Sundheim’s D1 Capital liquidated its stake in JPMorgan Chase & Co., jettisoning a position worth more than $1 billion as of March 31. Viking also decreased its JPMorgan stake, but started a new position in Bank of America Corp. Stan Druckenmiller’s Duquesne took a new position in Citigroup Inc. and has a small holding in JPMorgan. Berkshire Hathaway Inc., meanwhile, cut its position in Wells Fargo. ValueAct dumped its remaining stake in Morgan Stanley.GameStop Corp. was among the companies that skyrocketed during the Reddit-fueled trading frenzy at the beginning of the year. Maverick Capital exited its stake in the video-game retailer, valued at $88 million at the end of December, when the shares traded at $18.84. GameStop shares hit a record $347.51 on Jan. 27.Alibaba Group Holding Ltd. seemed to fall out of favor with some hedge funds in the first three months of the year as China’s crackdown on the technology sector weighed on the e-commerce giant. It was a top exit for Third Point and Coatue; Soroban Capital Partners trimmed its stake.George Soros’s investment firm was among those that capitalized on the distressed remains of Archegos. His Soros Fund Management snapped up shares of ViacomCBS Inc., Discovery Inc. and Baidu Inc. as they were being sold off in massive blocks during the collapse of Archegos at the end of March. Coatue also started smaller new positions in three of the names in the quarter: a $148 million stake in Farfetch Ltd., a $147 million position in RLX Technology Inc. and a $77 million holding in ViacomCBS. And D1 Capital added 124,000 shares of Shopify Inc. for a stake valued at $137 million. Elliott Management Corp. disclosed it held a $95 million stake in Discovery Inc.David Tepper’s Appaloosa also took a toehold in five of the stocks that Archegos had to divest, including Shopify, ViacomCBS, Discovery, Baidu and Iqiyi. The stakes had a combined value of $217 million at the end of March, and ranged in size from a $155 million investment in ViacomCBS to a $4.1 million bet on Shopify.Starboard Value jumped on a hot Wall Street trend: SPACs. The activist investor, which launched its own blank-check company last year, made relatively small investments in 18 such companies in the quarter, including ones being run by notable investors such as Michael Klein and Alex Rodriguez and private equity firms KKR & Co. and Warburg Pincus. Another activist investor, Keith Meister’s Corvex Management, also snapped up several SPAC names in the quarter.Michael Burry, the investor who rose to fame for making billions off bets against mortgage securities during the financial crisis, placed a sizable wager against Elon Musk’s Tesla Inc. Burry’s Scion Asset Management owned bearish puts against 800,100 shares of the electric-car maker, worth $534 million as of March 31, according to a regulatory filing Monday.(Updates with Amazon share performance in seventh paragraph.)More stories like this are available on bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Dublin, May 18, 2021 (GLOBE NEWSWIRE) -- The "Medical Enzyme Technology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type; Application, and Geography" report has been added to ResearchAndMarkets.com's offering. The global medical enzyme technology market is expected to reach US$ 6,700.00 million by 2028 from US$ 4,012.57 million in 2020; it is estimated to grow at a CAGR of 6.7% during 2021-2028.Enzymes play a crucial role in the metabolic activities of all organisms. They have an extensive range of applications in microbial biotechnology and diagnosis processes. Abnormalities in enzyme metabolism system leads to many metabolic diseases. Many enzymes are being widely used in the clinical examination as a specific disease marker. Further, medicinal enzymes can be used as medicines to treat a range of diseases. They are characterized by remarkable curative effect and insignificant side effects. For example, trypsin can be used to accelerate wound healing, dissolve blood clots, remove necrotic tissue, and inhibit contaminant growth (in cell cultures). L-asparaginase can be used to treat cancer by depriving nutrients needed for the growth of cancer cells. Protease (provide in the form of multi-enzyme tablets) can be used to treat dyspepsia; many proteases have anti-inflammatory properties. Moreover, lipase, superoxide dismutase, nattokinase, soybean meal plasmin, and thrombin, among others, can be used to treat various diseases. Enzymes are the preferred markers in various disease states such as myocardial infarction, jaundice, pancreatitis, cancer, and neurodegenerative disorders. They assist in diagnosis, prognosis, and assessment of response therapy. Furthermore, many enzymes are used as diagnostic reagents. Due to the unique enzyme characteristics of specificity, high-catalytic efficiency, and mild action conditions, the enzymatic diagnosis has become a reliable, simple, and rapid method. The medical enzyme technology market, by enzyme type, is segmented into digestive enzymes, thrombolytic enzymes, hydrolases, and endonucleases. The hydrolases segment held the largest share of the market in 2020; however, the thrombolytic enzymes segment is anticipated to register the highest CAGR of 7.2% during the forecast period.In terms of technique, the medical enzyme technology market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment held a larger market share in 2019. However, the market for normothermic machine perfusion is estimated to grow at a higher CAGR of 4.4% during the forecast period.The medical enzyme technology market, by application, is segmented into disease treatment, diagnostic tools, biomedical research, and others. The disease treatment segment held the largest share of the market in 2020, and the same segment is anticipated to register the highest CAGR of 7.1% in the market during the forecast period.The Central Drugs Standard Control Organization, Commission for Protection against Health Risks, Contract Research Organizations, and Drug Safety and Effectiveness Network are among the major secondary sources referred to while preparing the report on the medical enzyme technology market.Reasons to Buy Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the medical enzyme technology market.Highlights key business priorities in order to assist companies to realign their business strategies.The key findings and recommendations highlight crucial progressive industry trends in the global medical enzyme technology market, thereby allowing players across the value chain to develop effective long-term strategies.Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution Key Topics Covered: 1. Introduction1.1 Scope of the Study1.2 Research Report Guidance1.3 Market Segmentation1.3.1 Global Medical Enzyme Technology Market - By Enzyme Type1.3.2 Global Medical Enzyme Technology Market - By Application1.3.3 Global Medical Enzyme Technology Market - By Geography2. Medical Enzyme Technology Market - Key Takeaways3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research4. Medical Enzyme Technology Market - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 North America- PEST Analysis4.2.2 Europe- PEST Analysis4.2.3 Asia Pacific- PEST Analysis4.2.4 Middle East & Africa4.2.5 South & Central America4.3 Expert Opinion5. Medical Enzyme Technology Market - Key Market Dynamics5.1 Market Drivers5.1.1 Applications of Enzymes in Diagnosis and Disease Treatment5.1.2 Significant Increase in Research and Development Activities5.2 Market Restraints5.2.1 Handling and Safety Issues Related to Enzymes5.3 Market Opportunities5.3.1 Rising Production of Biopharmaceutical Products5.4 Future Trends5.4.1 Advancements in Enzyme Engineering5.5 Impact Analysis of Drivers and Restraints6. Medical Enzyme Technology Market - Global Analysis6.1 Global Medical Enzyme Technology Market Revenue Forecast and Analysis6.2 Global Medical Enzyme Technology Market, By Geography - Forecast and Analysis6.3 Market Positioning of Key Players7. Medical Enzyme Technology Market Analysis - By Enzyme Type7.1 Overview7.2 Medical Enzyme Technology Market Revenue Share, by Enzyme Type (2020-2028)7.3 Digestive Enzymes7.3.1 Overview7.3.2 Digestive Enzymes: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.3.3 L-asparaginase Market126.96.36.199 Overview188.8.131.52 L-asparaginase: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.3.4 Lactase Market184.108.40.206 Overview220.127.116.11 Lactase: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.3.5 Others Market18.104.22.168 Overview22.214.171.124 Others: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.4 Thrombolytic Enzymes7.4.1 Overview7.4.2 Thrombolytic Enzymes: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.4.3 Streptokinase Market126.96.36.199 Overview188.8.131.52 Streptokinase: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.4.4 Urokinase Market184.108.40.206 Overview220.127.116.11 Urokinase: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.4.5 Others Market18.104.22.168 Overview22.214.171.124 Others: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.5 Hydrolases Enzymes7.5.1 Overview7.5.2 Hydrolases: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.5.3 Hyaluronidase Market126.96.36.199 Overview188.8.131.52 Hyaluronidase: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.5.4 Lysozymes Market184.108.40.206 Overview220.127.116.11 Lysozymes: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.5.5 Others Market18.104.22.168 Overview22.214.171.124 Others: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.6 Endonucleases7.6.1 Overview7.6.2 Endonucleases: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.6.3 Benzonase126.96.36.199 Overview188.8.131.52 Benzonase: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)7.6.4 Others184.108.40.206 Overview220.127.116.11 Others: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)8. Medical Enzyme Technology Market Analysis - By Application8.1 Overview8.2 Medical Enzyme Technology Market Revenue Share, by Application (2020-2028)8.3 Disease Treatment8.3.1 Overview8.3.2 Disease Treatment: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)8.4 Diagnostic Tools8.4.1 Overview8.4.2 Diagnostic Tools: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)8.5 Biomedical Research8.5.1 Overview8.5.2 Biomedical Research: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)8.6 Others8.6.1 Overview8.6.2 Others: Medical Enzyme Technology Market - Revenue and Forecast to 2028 (US$ Million)9. Medical Enzyme Technology Market - Geographical Analysis9.1 North America9.2 Europe: Medical Enzyme Technology Market9.3 Asia Pacific9.4 South and Central America: Medical Enzyme Technology Market9.5 Middle East and Africa: Medical Enzyme Technology Market10. Impact Of COVID-19 Pandemic on Global Medical Enzyme Technology Market10.1 North America: Impact Assessment of COVID-19 Pandemic10.2 Europe: Impact Assessment of COVID-19 Pandemic10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic10.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic10.5 South & Central America: Impact Assessment of COVID-19 Pandemic11. Medical Enzyme Technology Market-Industry Landscape11.2 Growth Strategies Done by the Companies in the Market, (%)11.3 Organic Developments11.3.1 Overview11.3.2 Organic Developments Done by Companies11.4 Inorganic Developments11.4.1 Overview11.4.2 Inorganic Developments Done by Companies12. Company Profiles12.1 MERCK KGaA12.1.1 Key Facts12.1.2 Business Description12.1.3 Products and Services12.1.4 Financial Overview12.1.5 SWOT Analysis12.1.6 Key Developments12.2 THERMO FISHER SCIENTIFIC INC.12.2.1 Key Facts12.2.2 Business Description12.2.3 Products and Services12.2.4 Financial Overview12.2.5 SWOT Analysis12.2.6 Key Developments12.3 Novozymes12.3.1 Key Facts12.3.2 Business Description12.3.3 Products and Services12.3.4 Financial Overview12.3.5 SWOT Analysis12.3.6 Key Developments12.4 Takeda Pharmaceutical Company Limited12.4.1 Key Facts12.4.2 Business Description12.4.3 Products and Services12.4.4 Financial Overview12.4.5 SWOT Analysis12.4.6 Key Developments12.5 Agilent Technologies, Inc.12.5.1 Key Facts12.5.2 Business Description12.5.3 Products and Services12.5.4 Financial Overview12.5.5 SWOT Analysis12.5.6 Key Developments12.6 Genzyme Corporation12.6.1 Key Facts12.6.2 Business Description12.6.3 Products and Services12.6.4 Financial Overview12.6.5 SWOT Analysis12.6.6 Key Developments12.7 Asahi Kasei Corporation12.7.1 Key Facts12.7.2 Business Description12.7.3 Products and Services12.7.4 Financial Overview12.7.5 SWOT Analysis12.7.6 Key Developments12.8 Promega Corporation12.8.1 Key Facts12.8.2 Business Description12.8.3 Products and Services12.8.4 Financial Overview12.8.5 SWOT Analysis12.8.6 Key Developments12.9 Cytiva12.9.1 Key Facts12.9.2 Business Description12.9.3 Products and Services12.9.4 Financial Overview12.9.5 SWOT Analysis12.9.6 Key Developments12.10 Amano Enzyme Inc.12.10.1 Key Facts12.10.2 Business Description12.10.3 Products and Services12.10.4 Financial Overview12.10.5 SWOT Analysis12.10.6 Key Developments13. Appendix13.1 About the Publisher13.2 Glossary of TermsFor more information about this report visit https://www.researchandmarkets.com/r/3k7cef CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
JobNimbus and Xactware have announced a new restoration project management workflow integration.
A number of pot stocks have reported double- or even triple-digit balance sheet gains during the pandemic and surged to new all-time highs in the process. Small-cap pot stock Ayr Wellness (OTC: AYRW.F) owns a family of cannabis brands under which it sells everything from oil to terpenes to and edibles. The company also owns and operates a chain of marijuana dispensaries in five states: Arizona, Florida, Massachusetts, Nevada, and Pennsylvania.
As it’s announced that e-scooters are to be fitted with noise-emitting devices to warn pedestrians, Phoebe Luckhurst on London’s new menace
The Samsung Galaxy S20 is a popular Android alternative with many attractive features and affordable tariffs. The Samsung Galaxy S20 handset, first launched in March 2020, is fitted with a 6.2-inch screen, a powerful processor (Exynos 990), 12GB of RAM and 128GB of storage. What tariffs are available for the Samsung Galaxy S20 range?
Shares in the East Yorkshire-based food business jumped after it revealed plans to raise its dividend and staff bonuses.